home / stock / phrm:cc / phrm:cc news

PHRM:CC News and Press, Pharmather Holdings Ltd. From 09/16/22

Stock Information
Company Name: Pharmather Holdings Ltd.
Stock Symbol: PHRM:CC
Market: CNQC
Website: pharmather.com
Menu
PHRM:CC PHRM:CC Quote PHRM:CC Short PHRM:CC News PHRM:CC Articles PHRM:CC Message Board
Get PHRM:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
PHRM:CC - PharmaTher Announces Late-Breaking Abstract Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease at the MDS International Congress of Parkinson's

Ketamine was safe, well-tolerated with 100% of patients treated with ketamine demonstrating reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale (UDysRS) UDysRS showed a 51% reduction from baseline during Infusion 2 (p=0.003), 49% at 3-week (p=0.006) and 41%...
PHRM:CC - PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with KETARX(TM) Ketamine Patch

KETARX ™ Ketamine Patch demonstrated extended delivery of ketamine over 40 hours KETARX ™ Ketamine Patch offers flexible dosing through increased size, drug load or concentration of ketamine to better align with intramuscular and intravenous administration ...

PHRM:CC - PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson's Disease and Motor Disorders

TORONTO, July 13, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, announced today that the United States Patent and Trademark Office (“USPTOȁ...

PHRM:CC - PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch

Successfully delivered ketamine and KETABET™ ( ketamine and betaine) via microneedle patch, unlocking the potential for desired dosage forms and pharmacokinetic profiles Pursuing Phase 2 clinical studies in treatment-resistant depression and pain indications in ...
PHRM:CC - PharmaTher Announces Positive Results from Study of KETABET(TM) for Depression

KETABET™ ( Ketamine and Betaine) shown effectiveness as measured by the Clinician Administered Dissociative States Scale Study results are adequate to give an effect size in powering a placebo-controlled clinical study PharmaTher planning a Phase 2 clinica...

PHRM:CC - PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO

Wearable ketamine delivery device complements PharmaTher’s ketamine product portfolio, including injectable, intravenous, and microneedle patch PharmaTher aims to become a leader in specialty ketamine products for mental health, neurological and pain disorders TORON...

PHRM:CC - PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine Analogs

TORONTO, May 05, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce that the United States Patent and Trademark Office granted U...
PHRM:CC - PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update

Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion product, ketamine microneedle patch and ketamine wearable pump device for mental health, neurological, and pain disorders ...

PHRM:CC - PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation and Production Process of Ketamine and Ketamine Analogs

TORONTO, April 12, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce that PharmaTher has entered into an exclusive worldwide license...

PHRM:CC - PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson's Disease

100% of patients treated with ketamine demonstrated reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale Ketamine was well tolerated with no serious adverse events reported Study results are adequate to give an effect size in powering a Phase 3 cli...
Previous 10 Next 10